For Publishers
DiscoveryMetadataPeer reviewHostingPublishing
For Researchers
JoinPublishReviewCollect
Register
Blog
About
Search
Advanced search
My ScienceOpen
Search
For Publishers
For Researchers
Blog
About
1
views
24
references
 Top references
cited by
10
    
0 reviews
 Review
0
comments
 Comment
0
recommends
+1 Recommend
0 collections
    0
    shares
      300
      similar
       All similar
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Downregulation of Rab23 in Prostate Cancer Inhibits Tumor Growth In Vitro and In Vivo

      research-article

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Rab23, a novel member of the Rab GTPase family, was found to be implicated in the progression of some human cancers. However, what role Rab23 plays in prostate cancer (PCa) remains to be illustrated. In the present study, we investigated the expression pattern and roles of Rab23 in PCa. The study results showed that Rab23 was upregulated in PCa tissues and cell lines. Moreover, downregulation of Rab23 remarkably suppressed the proliferation, migration, and invasion of PCa cells. In addition, downregulation of Rab23 significantly downregulated the protein expression levels of Shh and Gli1. Furthermore, we found that the Gli1 inhibitor GANT-61 greatly enhanced the suppressive effect of Rab23 downregulation on PCa cells. In conclusion, we suggested Rab23 as a potential therapeutic target for PCa treatment.

          Related collections

          Most cited references24

          • Record: found
          • Abstract: found
          • Article: not found

          Cancer statistics, 2007.

          Ahmedin Jemal, Rebecca Siegel, Elizabeth Ward … (2007)
          Each year, the American Cancer Society (ACS) estimates the number of new cancer cases and deaths expected in the United States in the current year and compiles the most recent data on cancer incidence, mortality, and survival based on incidence data from the National Cancer Institute, Centers for Disease Control and Prevention, and the North American Association of Central Cancer Registries and mortality data from the National Center for Health Statistics. This report considers incidence data through 2003 and mortality data through 2004. Incidence and death rates are age-standardized to the 2000 US standard million population. A total of 1,444,920 new cancer cases and 559,650 deaths for cancers are projected to occur in the United States in 2007. Notable trends in cancer incidence and mortality rates include stabilization of the age-standardized, delay-adjusted incidence rates for all cancers combined in men from 1995 through 2003; a continuing increase in the incidence rate by 0.3% per year in women; and a 13.6% total decrease in age-standardized cancer death rates among men and women combined between 1991 and 2004. This report also examines cancer incidence, mortality, and survival by site, sex, race/ethnicity, geographic area, and calendar year, as well as the proportionate contribution of selected sites to the overall trends. While the absolute number of cancer deaths decreased for the second consecutive year in the United States (by more than 3,000 from 2003 to 2004) and much progress has been made in reducing mortality rates and improving survival, cancer still accounts for more deaths than heart disease in persons under age 85 years. Further progress can be accelerated by supporting new discoveries and by applying existing cancer control knowledge across all segments of the population.
          Article 0 comments Cited 639 times – based on 0 reviews     Review now
            Bookmark
            • Record: found
            • Abstract: not found
            • Article: not found

            Tumor metastasis: mechanistic insights and clinical challenges.

            Patricia S Steeg (2006)
            Article 0 comments Cited 204 times – based on 0 reviews     Review now
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              The RAB25 small GTPase determines aggressiveness of ovarian and breast cancers.

              Karen Smith-McCune, Kyosuke Yamada, Nelly Auersperg … (2004)
              High-density array comparative genomic hybridization (CGH) showed amplification of chromosome 1q22 centered on the RAB25 small GTPase, which is implicated in apical vesicle trafficking, in approximately half of ovarian and breast cancers. RAB25 mRNA levels were selectively increased in stage III and IV serous epithelial ovarian cancers compared to other genes within the amplified region, implicating RAB25 as a driving event in the development of the amplicon. Increased DNA copy number or RNA level of RAB25 was associated with markedly decreased disease-free survival or overall survival in ovarian and breast cancers, respectively. Forced expression of RAB25 markedly increased anchorage-dependent and anchorage-independent cell proliferation, prevented apoptosis and anoikis, including that induced by chemotherapy, and increased aggressiveness of cancer cells in vivo. The inhibition of apoptosis was associated with a decrease in expression of the proapoptotic molecules, BAK and BAX, and activation of the antiapoptotic phosphatidylinositol 3 kinase (PI3K) and AKT pathway, providing potential mechanisms for the effects of RAB25 on tumor aggressiveness. Overall, these studies implicate RAB25, and thus the RAB family of small G proteins, in aggressiveness of epithelial cancers.
              Article 0 comments Cited 146 times – based on 0 reviews     Review now
                Bookmark
                All references

                Author and article information

                Journal
                Journal ID (nlm-ta): Oncol Res
                Journal ID (iso-abbrev): Oncol Res
                Journal ID (publisher-id): OR
                Title: Oncology Research
                Publisher: Cognizant Communication Corporation (Elmsford, NY )
                ISSN (Print): 0965-0407
                ISSN (Electronic): 1555-3906
                Publication date Collection: 2017
                Publication date (Electronic): 26 January 2017
                Volume: 25
                Issue: 2
                Pages: 241-248
                Affiliations
                [1]*Department of Urology, Huaihe Hospital of Henan University , Kaifeng, Henan Province, P.R. China
                [2]†Antibody Drug Engineering Laboratory of Henan Province , Kaifeng, Henan Province, P.R. China
                Author notes

                1These authors provided equal contribution to this work.

                Address correspondence to Xinyi Du, Department of Urology, Huaihe Hospital of Henan University, No. 8 Baobei Road, Kaifeng 475000, Henan Province, P.R. China. Tel: +86-0378-3906000; Fax: +86-0378-3906000; E-mail: duxinyiuro@ 123456163.com
                Article
                Publisher ID: OR955
                DOI: 10.3727/096504016X14742891049118
                PMC ID: 7840735
                PubMed ID: 28277196
                SO-VID: 6f41e67a-9b29-4d96-a8de-11ea0806b2cc
                Copyright © Copyright © 2017 Cognizant, LLC.
                License:

                This article is licensed under a Creative Commons Attribution-NonCommercial NoDerivatives 4.0 International License.

                History
                Page count
                Figures: 4, Tables: 0, References: 26, Pages: 8
                Categories
                Subject: Article

                Keywords: rab23,proliferation,migration,invasion,prostate cancer (pca)
                Data availability:
                Keywords: rab23, proliferation, migration, invasion, prostate cancer (pca)

                Comments

                Comment on this article

                scite_

                Similar content300

                See all similar

                Cited by10

                See all cited by

                Most referenced authors517

                See all reference authors